Media Releases

2019

Pulmonx Closes $65 Million Financing and Adds Chief Financial Officer

On May 9, 2019

Financing to Expand the U.S. Launch and Global Commercialization of the Zephyr Valve, a Less Invasive Treatment Option for Severe Emphysema/COPD REDWOOD CITY, California, May 9, 2019 – Pulmonx Corporation, a global leader in diagnostic and therapeutic pulmonary device technologies, announced today the closing of an oversubscribed $65 million equity financing and the hiring of Derrick […]

Page 2 of 212

2018

FDA Approves Zephyr Endobronchial Valve for Treating Severe Emphysema

On June 29, 2018

REDWOOD CITY, Calif. – June 29, 2018 – Pulmonx® Corp. announced today that the U.S. Food and Drug Administration (FDA) has approved the Zephyr® Endobronchial Valve System for treating severe emphysema patients. The Zephyr Valve is the first minimally-invasive device approved in the United States for

On May 22, 2018

SAN DIEGO and REDWOOD CITY, Calif. – May 22, 2018 – Pulmonx® Corp. today announced positive one-year results from the U.S. LIBERATE pivotal trial of the Zephyr® Endobronchial Valve, a minimally-invasive treatment for severe emphysema, an advanced form of chronic obstructive pulmonary disease (COPD)....

On January 9, 2018

Zephyr EBVs are the Only Minimally-Invasive, Removable Devices for Emphysema with Validated Diagnostic Tool to Select Patients Likely to Benefit from Treatment

UK National Institute for Health and Care Excellence (NICE) Updates Endobronchial Valve Treatment Guidance to Standard Care

On November 20, 2017

REDWOOD CITY, Calif. – December 20, 2017 – Pulmonx® Corp. today announced that the UK's National Institute for Health and Care Excellence (NICE) has updated its guidance for endobronchial valves used to treat severe emphysema, an advanced form of chronic obstructive pulmonary disease (COPD), and now...

On September 8, 2017

REDWOOD CITY, Calif. – September 8, 2017 – Pulmonx® Corp. today announced the publication of positive six-month results from TRANSFORM, a multicenter, multinational, randomized clinical trial (RCT) of the Zephyr® Endobronchial Valve (EBV®) in the American Journal of Respiratory and Critical Care...

On May 23, 2017

Washington DC and Redwood City, Calif. – May 23, 2017 – Pulmonx, Inc. today announced the results of two multi-center, randomized clinical trials showing clinically meaningful improvements in lung function after treatment with the Zephyr® Endobronchial Valve (EBV) in emphysema patients without...

GOLD Treatment Recommendations for COPD Now Include Use of Endobronchial Valves to Treat Patients with Emphysema

On November 18, 2016

Redwood City, Calif. – November 18, 2016 – The Global Initiative for Chronic Obstructive Lung Disease (GOLD) issued a substantial revision to its COPD management recommendations that now includes bronchoscopic lung volume reduction with endobronchial valves as a treatment option for patients with...

On October 5, 2016

Redwood City, Calif. – October 5, 2016 – Pulmonx, a leader in interventional pulmonology, today announced completion of enrollment in its pivotal IDE study – the LIBERATE Trial – a randomized, controlled, multi-center study of the Zephyr® Endobronchial Valve (EBV) in patients with severe emphysema,...

On September 5, 2016

Results Published in American Journal of Respiratory and Critical Care Medicine Show Meaningful Improvements in Patient Lung Function, Exercise Tolerance and Quality of Life

On September 1, 2016

Cloud-Based Quantitative Computed Tomography (QCT) Analysis Service is Now Commercially Available

On May 18, 2016

Redwood City, Calif. – May 18, 2016 - Pulmonx®, a leader in interventional pulmonology, today announced positive one year results from the groundbreaking STELVIO trial. The STELVIO trial is the first randomized controlled study of Zephyr® Endobronchial Valves (EBV) in severe emphysema patients...

Pulmonx Names New Chief Executive Officer

On December 18, 2015

December 18, 2015, Redwood City, California - Pulmonx Corporation, a leader in interventional pulmonology, today announced that Glen French has joined the company as President, Chief Executive Officer and member of the Board of Directors. Mr. French posesses deep experience leading and transforming...

On December 9, 2015

New England Journal of Medicine Publishes Groundbreaking Study Demonstrating Benefits of Medical Device for Emphysema First Prospective, Randomized Controlled Study Using the Chartis System to Select Patients Confirms Clinical Superiority of Zephyr® EBV Therapy over Medical Management in Treating Emphysema Redwood City, Calif. – December 9, 2015 – Pulmonx Corporation, a leader in interventional pulmonology,...

On October 18, 2015

London, UK, October 28, 2015 – A clinical trial recently commenced at Royal Brompton Hospital to evaluate a minimally-invasive valve based treatment that may help patients suffering from severe emphysema breathe easier without surgery. Emphysema is a form of chronic obstructive pulmonary disease...

On September 28, 2015

REDWOOD CITY, Calif. – September 28, 2015 - Pulmonx®, a leader in interventional pulmonology, today announced the launch of a tablet version of its Chartis Pulmonary Assessment System, a diagnostic tool designed to identify optimal patients for Zephyr® Endobronchial Valve (EBV) therapy. The Chartis...

On July 1, 2015

REDWOOD CITY, Calif. – July 1, 2015 –Pulmonx®, a leader in interventional pulmonology, today announced publication in The Lancet of results from the BeLieVeR-HIFi clinical trial, the first successful sham-controlled trial of any minimally invasive emphysema device. BeLieVeR-HIFi is a prospective,...

On May 18, 2015

Denver, Colo. – May 18, 2015 –Pulmonx®, a leader in interventional pulmonology, today announced results from a retrospective analysis of the landmark VENT trial that demonstrated a statistically significant benefit in severe emphysema patients with homogeneous disease that received treatment with...

Pulmonx’s Zephyr® Endobronchial Valve Demonstrates Statistically and Clinically Significant Results in a Prospective, Randomized Controlled Trial

On September 9, 2015

September 09, 2014, Redwood City & Munich - The results of BeLieVeR-HIFi trial, the first double-blinded, randomized, controlled clinical trial to assess the impact of the Zephyr® Endobronchial Valve (EBV) for the treatment of emphysema, were presented today at the 2014 European Respiratory Society...

On May 19, 2014

Pulmonx Products Highlighted in Multiple Presentations at ATS 2014 May 19, 2014, Redwood City, California - Pulmonx, an emerging leader in interventional pulmonology, announced today that multiple clinical abstracts examining the diagnostic and therapeutic utility of its Chartis Pulmonary...

On April 24, 2014

April 24, 2014, Neuchâtel, Switzerland - Pulmonx, an emerging leader in interventional pulmonology, announced today that its Zephyr® Endobronchial Valve (EBV) was featured at the 18th World Congress for Bronchology and Interventional Pulmonology (WCBIP) in Kyoto, Japan in the poster presentation...

ERS interactive learning module on endoscopic lung volume reduction

On December 1, 2013

This interactive case-based module illustrates the endoscopic treatment of severe emphysema by implantation of one-way-valves; emphasizes that an accurate patient selection is crucial for good outcome following ELVR; underlining that - despite of low morbidity and mortality - a strict monitoring of...

On November 1, 2013

The J-catheter is designed to assist in the placement of valves in difficult anatomy. Its preformed distal curvature may improve distal bronchoscope articulation by a minimum of 25% compared with the standard EDC, enabling access to difficult or tortuous anatomy

On September 9, 2013

September 9, 2013, Barcelona, Spain - Pulmonx, an emerging leader in interventional pulmonology, announced that its endobronchial valve (EBV) therapy is a topic of eight different scientific presentations throughout the course of the European Respiratory Society Annual Congress.

On September 9, 2013

September 9, 2013, Barcelona, Spain - Pulmonx, an emerging leader in interventional pulmonology, is unveiling two new products at the 23rd Annual Congress of the ERS.

On July 19, 2013

July 19, 2013, Neuchatel, Switzerland - Pulmonx, an emerging leader in interventional pulmonology, today announced the launch of the Zephyr® 4.0 Low Profile Endobronchial Valve (4.0-LP).

Pulmonx Gains Regulatory Approval for Expanded Labeling for Emphysema Treatment

On August 1, 2018

Pulmonx Gains Regulatory Approval for Expanded Labeling for Emphysema Treatment New labeling clears the way for the treatment of many more patients. January 10, 2012, Neuchâtel, Switzerland – Pulmonx SARL today announced that its European notified body has granted CE approval for expanded labeling of its Zephyr® endobronchial valve (EBV). The approval was based upon an...

On August 1, 2018

Zephyr® Endobronchial Valve (EBV) therapy guided by Chartis®Assessment is effective in a broad range of patients. May 10, 2012 ,Peseux, Switzerland, Pulmonx, an emerging leader in interventional pulmonology, announced today that the European Respiratory Journal has published the results of the...

On August 1, 2018

Company Receives Approval to Revise CE Labeling August 29, 2012, Peseux, Switzerland – Pulmonx, an emerging leader in interventional pulmonology, announced today that its European notified body has granted CE approval for revised labeling of its Zephyr® Endobronchial Valve (EBV). The approval was...

On August 1, 2018

IDE for Study of Zephyr® Endobronchial Valve Approved August 27, 2012, Redwood City, CA, USA - Pulmonx, an emerging leader in interventional pulmonology, announced today that the U.S. Food and Drug Administration (FDA) has approved its request for an Investigational Device Exemption (IDE) to...

On August 29, 2012

August 29, 2012, Peseux, Switzerland – Pulmonx, an emerging leader in interventional pulmonology, announced today that its European notified body has granted CE approval for revised labeling of its Zephyr® Endobronchial Valve (EBV).

On August 27, 2012

August 27, 2012, Redwood City, CA, USA - Pulmonx, an emerging leader in interventional pulmonology, announced today that the U.S. Food and Drug Administration (FDA) has approved its request for an Investigational Device Exemption (IDE) to commence a multi-center pivotal clinical trial.

On May 10, 2012

May 10, 2012 ,Peseux, Switzerland, Pulmonx, an emerging leader in interventional pulmonology, announced today that the European Respiratory Journal has published the results of the Chartis®Multi-Centre study.

On January 10, 2012

January 10, 2012, Neuchâtel, Switzerland – Pulmonx SARL today announced that its European notified body has granted CE approval for expanded labeling of its Zephyr® endobronchial valve (EBV). The approval was based upon an independent review of clinical data from numerous studies including the recently completed Chartis multi-center study1 and the European VENT study (a randomized multi-center European trial of Zephyr EBV therapy)2.

Study Confirms Minimally-Invasive Pulmonx Therapy Effectively Treats Emphysema

On September 25, 2011

September 25, 2011, Amsterdam, Netherlands (ERS) – Pulmonx Inc. has just announced final results of its Chartis multi-centre study1, presented today at the European Respiratory Society’s 2011 Congress. This definitive data confirms that use of the Chartis® Pulmonary Assessment System to plan Zephyr® valve treatmentsis the key to successful EBV treatment of emphysema.

On March 18, 2011

May 18, 2011, Denver, CO (ATS) – Pulmonx Inc. has announced new clinical data from its Chartis multicenter study1, presented at the American Thoracic Society’s 2011 International Conference. This definitive data clearly demonstrates that by using the Chartis® Pulmonary Assessment System to plan Zephyr® valve treatments physicians can consistently treat a broad spectrum of emphysema patients.

Pulmonx Reports Scientific Publication and Presentations Highlighting Key Advances in Emphysema Treatment

On September 27, 2010

September 27, 2010, Neuchâtel, Switzerland – Pulmonx, an emerging leader in interventional pulmonology, announced today that the New England Journal of Medicine has published the results of the largest prospective, randomized, controlled study completed to date of endobronchial approaches to emphysema treatment, the VENT Study (Endobronchial Valve for Emphysema PalliatioN Trial).

On February 22, 2010

ences Rollout of Breakthrough New Products Redwood City, CA USA (February 22, 2010) – Pulmonx, an emerging leader in interventional pulmonology, announced today that it has concluded an agreement for a new round of equity financing from an investment syndicate led by two new investors. The company also announced that it plans to use this capital to support the international commercial launch of its Zephyr®Endobronchial Valve (EBV), and its recently approved Chartis® Pulmonary Assessment System.

Media Releases

HEALTHCARE PROFESSIONAL USE ONLY